Flores-Contreras Elda A, González-González Everardo, Trujillo-Rodríguez Gerardo de Jesús, Rodríguez-Sánchez Iram P, Ancer-Rodríguez Jesús, Pérez-Maya Antonio Alí, Alvarez-Cuevas Salomon, Martinez-Fierro Margarita L, Marino-Martínez Iván A, Garza-Veloz Idalia
Departamento de Patología, Facultad de Medicina, Universidad Autónoma de Nuevo León, Francisco I. Madero y Dr. E. Aguirre Pequeño s/n, Mitras Centro, Monterrey 64460, Mexico.
Molecular Medicine Laboratory, Unidad Académica de Medicina Humana y Ciencias de la Salud, Universidad Autónoma de Zacatecas, Zacatecas 98160, Mexico.
Pathogens. 2024 Aug 2;13(8):653. doi: 10.3390/pathogens13080653.
The human papillomavirus (HPV) is a non-enveloped DNA virus transmitted through skin-to-skin contact that infects epithelial and mucosal tissue. It has over 200 known genotypes, classified by their pathogenicity as high-risk and low-risk categories. High-risk HPV genotypes are associated with the development of different types of cancers, including cervical cancer, which is a leading cause of mortality in women. In clinical practice and the market, the principal tests used to detect HPV are based on cytology, hybrid detection, and qPCR. However, these methodologies may not be ideal for the required timely diagnosis. Tests have been developed based on isothermal nucleic acid amplification tests (INAATs) as alternatives. These tests offer multiple advantages over the qPCR, such as not requiring specialized laboratories, highly trained personnel, or expensive equipment like thermocyclers. This review analyzes the different INAATs applied for the detection of HPV, considering the specific characteristics of each test, including the HPV genotypes, gene target, the limit of detection (LOD), detection methods, and detection time. Additionally, we discuss the tests available on the market that are approved by the Food and Drug Administration (FDA). Finally, we address the challenges and potential solutions for the large-scale implementation of INAATs, particularly in rural or underserved areas.
人乳头瘤病毒(HPV)是一种通过皮肤接触传播的无包膜DNA病毒,可感染上皮组织和黏膜组织。它有200多种已知基因型,根据其致病性分为高危和低危类别。高危HPV基因型与不同类型癌症的发生有关,包括宫颈癌,宫颈癌是女性死亡的主要原因。在临床实践和市场上,用于检测HPV的主要检测方法基于细胞学、杂交检测和定量聚合酶链反应(qPCR)。然而,这些方法对于所需的及时诊断可能并不理想。基于等温核酸扩增试验(INAATs)开发了一些检测方法作为替代方案。这些检测方法相对于qPCR具有多个优势,例如不需要专门的实验室、训练有素的人员或像热循环仪这样昂贵的设备。本综述分析了应用于检测HPV的不同INAATs,考虑了每种检测方法的具体特征,包括HPV基因型、基因靶点、检测限(LOD)、检测方法和检测时间。此外,我们还讨论了美国食品药品监督管理局(FDA)批准的市场上可用的检测方法。最后,我们探讨了大规模实施INAATs面临的挑战和潜在解决方案,特别是在农村或医疗服务不足的地区。